Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128885) titled 'Real-world study of Trastuzumab Rezetecan in HER2-mutated or low-expressing pan-tumor types after failure of standard treatment' on July 27.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The first affiliated hospital of anhui medical university
Condition:
Pan-tumor types with HER2 mutation or low expression that fail standard treatment
Intervention:
Queue F: Other tumor types:None
Queue A: Biliary tract cancer group:None
Queue E: Gynecological tumors:None
Queue C: Urothelial carcinoma:None
Queue D: Head and neck tumors:None
Recruitment Status: Not Recruiting
Phase: 4
Date ...